231 related articles for article (PubMed ID: 33451088)
21. Neuroprotective potential of high-dose biotin.
McCarty MF; DiNicolantonio JJ
Med Hypotheses; 2017 Nov; 109():145-149. PubMed ID: 29150274
[TBL] [Abstract][Full Text] [Related]
22. Meeting report: cGMP matters.
Kemp-Harper B; Feil R
Sci Signal; 2008 Mar; 1(9):pe12. PubMed ID: 18319447
[TBL] [Abstract][Full Text] [Related]
23. Cyclic GMP synthesis by human retinal pigment epithelial cells is mainly mediated via the particulate guanylyl cyclase pathway.
Diederen RM; La Heij EC; Markerink-van Ittersum M; Kijlstra A; Hendrikse F; de Vente J
Ophthalmic Res; 2007; 39(1):55-9. PubMed ID: 17179739
[TBL] [Abstract][Full Text] [Related]
24. Traumatic injury of the spinal cord and nitric oxide.
Marsala J; Orendácová J; Lukácová N; Vanický I
Prog Brain Res; 2007; 161():171-83. PubMed ID: 17618976
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease.
Sheng J; Zhang S; Wu L; Kumar G; Liao Y; Gk P; Fan H
Front Aging Neurosci; 2022; 14():1019187. PubMed ID: 36268188
[TBL] [Abstract][Full Text] [Related]
26. The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase.
Ota KT; Pierre VJ; Ploski JE; Queen K; Schafe GE
Learn Mem; 2008 Oct; 15(10):792-805. PubMed ID: 18832566
[TBL] [Abstract][Full Text] [Related]
27. Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory.
Palmeri A; Ricciarelli R; Gulisano W; Rivera D; Rebosio C; Calcagno E; Tropea MR; Conti S; Das U; Roy S; Pronzato MA; Arancio O; Fedele E; Puzzo D
J Neurosci; 2017 Jul; 37(29):6926-6937. PubMed ID: 28626017
[TBL] [Abstract][Full Text] [Related]
28. The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer's disease: A review.
Ahmad N; Lesa KN; Sudarmanto A; Fakhrudin N; Ikawati Z
Front Pharmacol; 2022; 13():1070677. PubMed ID: 36618909
[TBL] [Abstract][Full Text] [Related]
29. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells.
Fiscus RR
Neurosignals; 2002; 11(4):175-90. PubMed ID: 12393944
[TBL] [Abstract][Full Text] [Related]
30. cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.
Reierson GW; Guo S; Mastronardi C; Licinio J; Wong ML
Curr Neuropharmacol; 2011 Dec; 9(4):715-27. PubMed ID: 22654729
[TBL] [Abstract][Full Text] [Related]
31. cGMP-phosphodiesterase antagonists inhibit Ca2+-influx in Dictyostelium discoideum and bovine cyclic-nucleotide-gated-channel.
Lusche DF; Kaneko H; Malchow D
Eur J Pharmacol; 2005 Apr; 513(1-2):9-20. PubMed ID: 15878705
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.
Jackson EB; Mukhopadhyay S; Tulis DA
Curr Vasc Pharmacol; 2007 Jan; 5(1):1-14. PubMed ID: 17266609
[TBL] [Abstract][Full Text] [Related]
33. Postsynaptic NO/cGMP increases NMDA receptor currents via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus.
Neitz A; Mergia E; Imbrosci B; Petrasch-Parwez E; Eysel UT; Koesling D; Mittmann T
Cereb Cortex; 2014 Jul; 24(7):1923-36. PubMed ID: 23448871
[TBL] [Abstract][Full Text] [Related]
34. Hyperammonemia impairs long-term potentiation in hippocampus by altering the modulation of cGMP-degrading phosphodiesterase by protein kinase G.
Monfort P; Muñoz MD; Felipo V
Neurobiol Dis; 2004 Feb; 15(1):1-10. PubMed ID: 14751765
[TBL] [Abstract][Full Text] [Related]
35. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
36. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
37. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
38. C-type natriuretic peptide regulation of guanosine-3',5'-cyclic monophosphate production in human endothelial cells.
Rautureau Y; Gowers I; Wheeler-Jones CP; Baxter GF
Auton Autacoid Pharmacol; 2010 Jul; 30(3):185-92. PubMed ID: 20085572
[TBL] [Abstract][Full Text] [Related]
39. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Prickaerts J; Heckman PRA; Blokland A
Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
[TBL] [Abstract][Full Text] [Related]
40. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
